• SpliSense initiates Phase 2b trial of SPL84 inhaled antisense oligonucleotide for the treatment of cystic fibrosis

  SpliSense announced that it has initiated the Phase 2b portion of the SPL84-02 trial of the SPL84 inhaled antisense oligonucleotide in CF patients with the 3849+10kb C→T splicing mutation in the CFTR gene. The Phase… [Read more . . .]

• FDA clears IND for Phase 1b trial of SMSbiotech’s inhaled stem cell therapy in patients with COPD

  California-based SMSbiotech announced that the FDA has cleared its IND for a Phase 1b trial of its inhaled small mobile stem (SMS) cell therapy in patients with COPD and that the company intends to initiate… [Read more . . .]

• Ritedose Corporation names Carolyn Berg as VP of Strategic Growth

  US-based CDMO Ritedose Corporation, which manufactures its own inhalation products in addition to offering contract manufacturing services, has announced the appointment of experienced inhalation business executive Carolyn Berg as VP of Strategic Growth. Berg was most recently… [Read more . . .]

• FDA approves Aurobindo’s generic beclomethasone MDI

  According to Aurobindo Pharma, the FDA has issued a final approval of the company’s ANDA for 40 mcg and 80 mcg dose versions of a generic equivalent of Teva’s QVAR beclomethasone HFA MDI for the… [Read more . . .]

• Zeteo Biomedical announces the launch of its new AriesMR active DPI

  Drug delivery specialist Zeteo Biomedical has announced the availability of its first device for delivery to the lung, the AriesMR DPI, which the company describes as “a reloadable active dry powder inhaler designed for controlled… [Read more . . .]

• Agomab reports results from Phase 1 study of AGMB-447 inhaled ALK5 inhibitor

• Cystic Fibrosis Foundation to make strategic investment of up to $7.3 million in Ride Therapeutics to support development of inhaled genetic therapies for CF

• FDA clears IND for Nasus’s NS002 epinephrine nasal powder for the treatment of anaphylaxis

• Aptar and MGH partner on development of platform to aid development of nose-to-brain therapies

• Hikma announces regulatory submissions for its epinephrine nasal spray in the US, UK, Europe, and Canada

More news . . .